Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics pioneered selinexor to block nuclear export; now its SEC reports are the next puzzle. Every 10-K outlining XPOVIO revenue, each 10-Q updating trial enrolment, and the swift 8-K announcing FDA designations hit EDGAR fast—yet remain locked in technical jargon. If you have ever searched “Karyopharm Therapeutics SEC filings explained simply” or asked, “How do I read a Karyopharm Therapeutics quarterly earnings report 10-Q filing?” you know the challenge of turning dense biotech disclosures into actionable insight.
Stock Titan solves that challenge with AI-powered analysis. Our engine reads every page the moment it’s filed, highlights new risk-factor language and converts tables into plain English. Want alerts for “Karyopharm Therapeutics insider trading Form 4 transactions” or “Karyopharm Therapeutics executive stock transactions Form 4”? We push them in real time, complete with context. Prefer the long view? Each upload arrives with an AI summary that makes a “Karyopharm Therapeutics annual report 10-K simplified.”
Investors following drug development need specifics: cash burn, partnership milestones, clinical data triggers. In the 10-Q we flag R&D spend by trial; the DEF 14A delivers “Karyopharm Therapeutics proxy statement executive compensation” comparisons; and our feed labels every “Karyopharm Therapeutics 8-K material events explained” link. Add “Karyopharm Therapeutics earnings report filing analysis,” Form S-3 shelf registrations, and “Karyopharm Therapeutics Form 4 insider transactions real-time,” and you have one searchable workspace—powered by AI—to understand the company before the market does.
Karyopharm Therapeutics (KPTI) Chief Accounting Officer Kristin Abate reported a sale of company common stock on 09/03/2025. The Form 4 shows a broker-assisted sale of 12 shares at $6.78 per share executed under a durable automatic sale instruction plan adopted May 27, 2021, to satisfy withholding tax from vested restricted stock units. After the transaction Abate beneficially owns 9,463 shares directly. The filing is signed by an attorney-in-fact on behalf of Abate on 09/04/2025. The sale is reported as non-discretionary and intended solely for tax withholding.
Karyopharm Therapeutics Inc. filed a Form S-8 to register an additional 450,000 shares of common stock under its 2022 Equity Incentive Plan, as amended. The filing incorporates prior Form S-8 registrations for the same plan by reference and makes those shares available for issuance as awards to employees and directors. Exhibits listed include the Restated Certificate, Third Amended and Restated By-Laws, counsel opinion and consent, auditor consent, the amended plan text and a filing fee table; the registration statement is signed by the company’s authorized officers and directors.
Karyopharm Therapeutics (KPTI) reported total revenue of $37.9 million for the quarter and $67.9 million year-to-date, driven primarily by U.S. product sales of XPOVIO (net product revenue of $29.7 million in Q2). The company recorded a net loss of $37.3 million for the quarter and $60.7 million for the six months ended June 30, 2025. Cash and short-term investments totaled approximately $51.7 million at June 30, 2025, while total assets were $104.9 million against $343.8 million of liabilities, resulting in a stockholders' deficit of $238.9 million.
The balance sheet shows near-term funding pressures: convertible 2025 Notes of $24.5 million mature October 15, 2025; a $100.0 million senior secured Term Loan (carrying $95.8 million) matures May 2028; and 2029 Notes (principal $116.0 million, carrying $62.7 million) mature in 2029. Management discloses "substantial doubt" about the company’s ability to continue as a going concern within one year and is evaluating strategic and financing alternatives; the company reduced headcount by ~20% as part of cost management.
Karyopharm Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The Form 8-K states the full press release with details is furnished as Exhibit 99.1 and is incorporated by reference into the report.
The filing clarifies that the information in this report and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 liability or automatic incorporation by reference in other Securities Act or Exchange Act filings. The Form 8-K itself does not include the financial figures in-line; investors must review Exhibit 99.1 for the substantive results.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) filed a Form 8-K on 11-Jul-2025 detailing material liquidity and operational actions.
The company disclosed that it held confidential discussions with new and existing investors to extend its cash runway; however, no financing agreement has been reached. To comply with confidentiality agreements, it published the related investor presentation (the “Cleansing Materials”) as Exhibit 99.1.
The Board is actively evaluating strategic alternatives that could include a merger or sale of the company, in- or out-of-court restructurings, or refinancing of existing debt. Management cautions that there is no assurance any transaction will occur or what terms might apply.
To conserve cash, Karyopharm is implementing a 20 % workforce reduction, with one-time charges expected to be immaterial. The company intends to keep supporting commercial sales of XPOVIO for multiple myeloma and to advance ongoing Phase 3 trials in myelofibrosis and endometrial cancer.
The filing reiterates forward-looking risk factors, including substantial doubt about the company’s ability to continue as a going concern absent additional capital.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
